AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39542489 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed mobilisation (GDM) during hospitalisation, which includes personal goal setting and a short session of patient education through a physiotherapist.
Number of subjects: 162
Study 39542489 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 162
Study 39542642 — intervention group
Group type: COMPARATOR
Intervention: US-TAP block
Number of subjects: 340
Study 39542642 — intervention group
Group type: COMPARATOR
Intervention: L-TAP block
Number of subjects: 340
Study 39542655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined paclitaxel and chemokine modulatory regimen (CKM) including rintatolimod, IFN-α2b, and celecoxib
Number of subjects: 9
Study 39542655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined paclitaxel and CKM regimen
Number of subjects: 9
Study 39542948 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 160
Study 39542995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovateltide (0.3 µg/kg) administered intravenously in three doses at 3 ± 1 h intervals on Days 1, 3, and 6.
Number of subjects: 158
Study 39542995 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline).
Number of subjects: 158
Study 39543001 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg BUP-XR injection in the upper arm
Number of subjects: 88
Study 39543001 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg BUP-XR injection in the thigh
Number of subjects: 88
Study 39543001 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg BUP-XR injection in the buttocks
Number of subjects: 88
Study 39543001 — intervention group
Group type: COMPARATOR
Intervention: 300-mg BUP-XR injection in the abdomen (reference)
Number of subjects: 88
Study 39543001 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluations including treatment-emergent adverse events and assessments of injection site pain, tenderness, erythema, induration, and swelling
Number of subjects: 88
Study 39543185 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored anti-smoking messages
Number of subjects: 966
Study 39543185 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored messages
Number of subjects: 966
Study 39543304 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) group (n=34) - 8-week program, three sessions per week, supplemented by an educational class once per week.
Number of subjects: 54
Study 39543304 — intervention group
Group type: COMPARATOR
Intervention: Educational (EDU) group (n=20) - attended an educational class once per week and encouraged to perform moderate-to-vigorous physical activity on their own.
Number of subjects: 54
Study 39543340 — intervention group
Group type: EXPERIMENTAL
Intervention: NEIVATECH system (9 hours of therapy, 18 half-hour sessions over 1 month)
Number of subjects: 0
Study 39543502 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a Learning Health Care Network (LHCN) across early psychosis programs
Number of subjects: 0
Study 39543502 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of measurement-based care
Number of subjects: 0
Study 39543502 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 0
Study 39543515 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL! program (Combined Lifestyle Intervention)
Number of subjects: 50
Study 39543515 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 50
Study 39543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 800
Study 39543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone exposure
Number of subjects: 800
Study 39543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional assessment of functional outcomes
Number of subjects: 800
Study 39543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone questionnaires
Number of subjects: 800
Study 39543521 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person study visit
Number of subjects: 800
Study 39543521 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry
Number of subjects: 800
Study 39543527 — intervention group
Group type: EXPERIMENTAL
Intervention: ABOi-RAKT
Number of subjects: 239
Study 39543527 — intervention group
Group type: COMPARATOR
Intervention: ABOi-OKT
Number of subjects: 239
Study 39543578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-screws with a rough, titanium oxide-coated surface
Number of subjects: 16
Study 39543590 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric-based identification method
Number of subjects: 23
Study 39543590 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposition method
Number of subjects: 23
Study 39543590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex determination function
Number of subjects: 23
Study 39543593 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression (C1) using an individual tray with zinc oxide eugenol
Number of subjects: 15
Study 39543593 — intervention group
Group type: COMPARATOR
Intervention: One-step simplified impression (C2) using a stock tray with irreversible hydrocolloid
Number of subjects: 15
Study 39543593 — intervention group
Group type: COMPARATOR
Intervention: Digital impression without AI scanning (D1)
Number of subjects: 15
Study 39543593 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impression with AI scanning (D2)
Number of subjects: 15
Study 39543593 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified digital impression (D3)
Number of subjects: 15
Study 39543697 — intervention group
Group type: EXPERIMENTAL
Intervention: Locavore-I-SF score
Number of subjects: 834
Study 39543718 — intervention group
Group type: EXPERIMENTAL
Intervention: Community navigation intervention
Number of subjects: 80
Study 39543718 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment
Number of subjects: 80
Study 39543756 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients surviving the first year after admission
Number of subjects: 140008
Study 39543756 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients excluding cardio-thoracic admissions
Number of subjects: 140008
Study 39543756 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of ICU patients ≥75 years old surviving the first year
Number of subjects: 140008
Study 39543756 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients with acute-on-chronic respiratory failure
Number of subjects: 140008
Study 39543756 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients with other respiratory causes
Number of subjects: 140008
Study 39543756 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients admitted for septic shock
Number of subjects: 140008
Study 39543797 — intervention group
Group type: EXPERIMENTAL
Intervention: Neofunctional deep breathing (NDB) technique
Number of subjects: 44
Study 39543797 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention
Number of subjects: 44
Study 39544014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergothioneine (25 mg per capsule, taken 3 times a week for one year)
Number of subjects: 19
Study 39544014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taken 3 times a week for one year)
Number of subjects: 19
Study 39544430 — intervention group
Group type: EXPERIMENTAL
Intervention: NabPaclitaxel-PIPAC
Number of subjects: 0
Study 39544430 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic NabPaclitaxel-Gemcitabine
Number of subjects: 0
Study 39544430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of NabPaclitaxel-PIPAC and systemic NabPaclitaxel-Gemcitabine
Number of subjects: 0
Study 39544897 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational products (amlitelimab and nerandomilast)
Number of subjects: 0
Study 39544897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39544899 — intervention group
Group type: EXPERIMENTAL
Intervention: Avenciguat
Number of subjects: 0
Study 39544899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39544960 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent with phacoemulsification (phaco-iStent)
Number of subjects: 71
Study 39544960 — intervention group
Group type: COMPARATOR
Intervention: phacoemulsification alone (control group)
Number of subjects: 71
Study 39545359 — intervention group
Group type: EXPERIMENTAL
Intervention: FirmTech device
Number of subjects: 50
Study 39545359 — intervention group
Group type: COMPARATOR
Intervention: Eddie by Giddy device
Number of subjects: 50
Study 39545423 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of disease incurability
Number of subjects: 251
Study 39545423 — intervention group
Group type: EXPERIMENTAL
Intervention: Being aware of disease incurability
Number of subjects: 251
Study 39545423 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty about disease incurability
Number of subjects: 251
Study 39545451 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference adalimumab (cH)
Number of subjects: 0
Study 39545451 — intervention group
Group type: COMPARATOR
Intervention: Switching between reference adalimumab and GP2017 (H2H)
Number of subjects: 0
Study 39545461 — intervention group
Group type: EXPERIMENTAL
Intervention: QHRD106 (18,900 IU single dose)
Number of subjects: 94
Study 39545461 — intervention group
Group type: EXPERIMENTAL
Intervention: QHRD106 (8,400 IU multiple doses)
Number of subjects: 94
Study 39545461 — intervention group
Group type: COMPARATOR
Intervention: UKN (0.15 PNA units intravenously for 7 days)
Number of subjects: 94
Study 39545461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 39545610 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus PD-1 inhibitor and radiotherapy
Number of subjects: 433
Study 39545610 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 433
Study 39545836 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Caring Theory-based breastfeeding education and support program
Number of subjects: 100
Study 39545836 — intervention group
Group type: COMPARATOR
Intervention: Standard breastfeeding training in a childbirth education class (control)
Number of subjects: 100
Study 39545967 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily iTBS
Number of subjects: 158
Study 39545967 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily iTBS
Number of subjects: 158
Study 39545967 — intervention group
Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 158
Study 39546030 — intervention group
Group type: EXPERIMENTAL
Intervention: 80CS_20G (coarse semolina with 20% gluten)
Number of subjects: 16
Study 39546030 — intervention group
Group type: COMPARATOR
Intervention: 80FS_20G (fine semolina with 20% gluten)
Number of subjects: 16
Study 39546030 — intervention group
Group type: COMPARATOR
Intervention: 95FS_5G (fine semolina with 5% gluten)
Number of subjects: 16
Study 39546040 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption (50 g daily)
Number of subjects: 34
Study 39546129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 1208
Study 39546129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ruxolitinib cream
Number of subjects: 1208
Study 39546129 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 1208
Study 39546311 — intervention group
Group type: EXPERIMENTAL
Intervention: OBLS education (blended learning curriculum with simulation-based training)
Number of subjects: 46
Study 39546315 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Sky School Program (nature-based intervention), 2 hours per week for 12 weeks
Number of subjects: 1015
Study 39546315 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Sky School Program (nature-based intervention)
Number of subjects: 1015
Study 39546315 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual classes)
Number of subjects: 1015
Study 39546314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Home Treatment (IHT)
Number of subjects: 200
Study 39546348 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-oSurg (web-based communication intervention)
Number of subjects: 24
Study 39546348 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative one-to-one semistructured interviews
Number of subjects: 24
Study 39546477 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate office-based vergence/accommodative therapy with movement (OBVAM)
Number of subjects: 100
Study 39546477 — intervention group
Group type: COMPARATOR
Intervention: Delayed OBVAM (by six weeks)
Number of subjects: 100
Study 39546477 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate OBVAM
Number of subjects: 100
Study 39546477 — intervention group
Group type: COMPARATOR
Intervention: Delayed OBVAM
Number of subjects: 100
Study 39546502 — intervention group
Group type: EXPERIMENTAL
Intervention: glargine U100
Number of subjects: 5047
Study 39546502 — intervention group
Group type: EXPERIMENTAL
Intervention: glimepiride
Number of subjects: 5047
Study 39546502 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 5047
Study 39546502 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 5047
Study 39546625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bigfoot Unity Diabetes Management System
Number of subjects: 102
Study 39546748 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus mini-hyper-CVD (cyclophosphamide, vincristine, dexamethasone alternating with methotrexate and cytarabine)
Number of subjects: 19
Study 39546748 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus mini-hyper-CVD
Number of subjects: 19
Study 39546931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil (gemogenovatucel-T)
Number of subjects: 82
Study 39546931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 39546957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed based on a Cox regression model incorporating 10 variables (age, male sex, smoking status, waist circumference, systolic blood pressure, fasting glucose, lipid abnormalities, antihypertensive, glucose-lowering, and lipid-lowering medications)
Number of subjects: 7933
Study 39546957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 7933
Study 39547230 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AAV8.TBG.hARSB gene therapy (single intravenous infusion)
Number of subjects: 4
Study 39547230 — intervention group
Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 4
Study 39547252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with preoperative radiotherapy and surgery
Number of subjects: 143
Study 39547252 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy and surgery (control group)
Number of subjects: 143
Study 39547249 — intervention group
Group type: EXPERIMENTAL
Intervention: FYTF-919 (Zhongfeng Xingnao) oral solution, 33 mL every 8 hours for 28 days (or 25 mL via nasogastric tube if swallowing impaired)
Number of subjects: 1648
Study 39547249 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matching appearance and administration as FYTF-919
Number of subjects: 1648
Study 39547249 — intervention group
Group type: EXPERIMENTAL
Intervention: FYTF-919
Number of subjects: 1648
Study 39547249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1648
Study 39547694 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs in RCTs
Number of subjects: 5654
Study 39547694 — intervention group
Group type: COMPARATOR
Intervention: PsABio
Number of subjects: 5654
Study 39547832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation with prolonged dual antiplatelet therapy (DAPT) for 36 months
Number of subjects: 505
Study 39547832 — intervention group
Group type: COMPARATOR
Intervention: Bioresorbable vascular scaffold (BVS) implantation with shorter DAPT duration
Number of subjects: 505
Study 39547832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation with prolonged DAPT
Number of subjects: 505
Study 39547931 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 1064
Study 39547931 — intervention group
Group type: COMPARATOR
Intervention: c-IVF
Number of subjects: 1064
Study 39547948 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality feedback report with tailored self-care tips
Number of subjects: 372
Study 39547948 — intervention group
Group type: COMPARATOR
Intervention: Generic reading on personality theory
Number of subjects: 372
Study 39547955 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation plus Care as Usual (BA + CAU)
Number of subjects: 153
Study 39547955 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 153
Study 39547981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug targets gene variants (specific SNPs not detailed)
Number of subjects: 0
Study 39548016 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 9971
Study 39548016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9971
Study 39548019 — intervention group
Group type: EXPERIMENTAL
Intervention: Equimolar oxygen-nitrous oxide (EMONO)
Number of subjects: 677
Study 39548032 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention in the emergency department
Number of subjects: 104
Study 39548032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physiotherapy intervention)
Number of subjects: 104
Study 39548306 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF only (G)
Number of subjects: 0
Study 39548306 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy/G-CSF (CG)
Number of subjects: 0
Study 39548320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Number of subjects: 0
Study 39548320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39548414 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO), n = 35
Number of subjects: 71
Study 39548414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control), n = 36
Number of subjects: 71
Study 39548414 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 71
Study 39548414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 39548423 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses showing cartoons in sign language (Study group)
Number of subjects: 40
Study 39548423 — intervention group
Group type: COMPARATOR
Intervention: Conventional behavior management approach (Control group)
Number of subjects: 40
Study 39548456 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive targeted sugar bait (ATSB) stations (0.11% dinotefuran w/w) maintained on exterior walls for 7 months (December-June) during high malaria transmission season.
Number of subjects: 4494
Study 39548456 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no ATSB) in the context of standard of care vector control (insecticide-treated nets and/or indoor residual spraying).
Number of subjects: 4494
Study 39548456 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive targeted sugar bait (ATSB) stations (0.11% dinotefuran w/w).
Number of subjects: 4494
Study 39548456 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no ATSB).
Number of subjects: 4494
Study 39548476 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication during consultation with clinicians (ophthalmologist/oncologist)
Number of subjects: 250
Study 39548476 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with the information received
Number of subjects: 250
Study 39548560 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 kHz KHFAC stimulation
Number of subjects: 34
Study 39548560 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 kHz KHFAC stimulation
Number of subjects: 34
Study 39548560 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 kHz KHFAC stimulation
Number of subjects: 34
Study 39548560 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 34
Study 39548582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo diterpene lactone meglumine (GDLM)
Number of subjects: 3219
Study 39548582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3219
Study 39548608 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabat rehabilitation
Number of subjects: 72
Study 39548608 — intervention group
Group type: COMPARATOR
Intervention: Mime therapy
Number of subjects: 72
Study 39548607 — intervention group
Group type: EXPERIMENTAL
Intervention: Illioinguinal/iliohypogastric nerve block with 20 ml of 0.25% ropivacaine
Number of subjects: 60
Study 39548607 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration with 10 ml of 0.25% ropivacaine
Number of subjects: 60
Study 39548607 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 39548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 60
Study 39549022 — intervention group
Group type: EXPERIMENTAL
Intervention: IN FOCUS (synchronous, virtual mind-body group resiliency intervention)
Number of subjects: 64
Study 39549022 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC; synchronous, virtual community group support referral)
Number of subjects: 64
Study 39549213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (dietary intervention)
Number of subjects: 55
Study 39549308 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT)
Number of subjects: 30
Study 39549308 — intervention group
Group type: COMPARATOR
Intervention: Classic rehabilitation strength training (CRST)
Number of subjects: 30
Study 39549539 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIM-intervention (health technology, motivational interviewing, feedback, and goal setting) implemented in prenatal visits continuing to 12 weeks postpartum.
Number of subjects: 54
Study 39549539 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 54
Study 39549554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of spermidine, nicotinamide, PEA, and OEA supplements
Number of subjects: 5